Last updated on: 16/08/2011
Name of organisation
1) Department/Research groupTeratology Information Service, Helsinki
2) Organisation/affiliationHUSLAB
Short Name in the inventoryTIS Helsinki
Administrative Contact
Title Dr
Last name Malm
First name Heli
Address line 1Tukholmankatu 17
Address line 2
Address line 3
CityHelsinki
Postcode00029 HUS
CountryFinland
Phone number (incl. country code)358947176589
Alternative phone number
Fax number (incl. country code)
Scientific Contact
Title Dr
Last name Malm
First name Heli
Address line 1Tukholmankatu 17
Address line 2
Address line 3
CityHelsinki
Postcode
CountryFinland
Phone number (incl. country code)358947176589
Alternative phone number
Fax number (incl. country code)
2. Description
The Teratology Information Service is affiliated to the Poison Information Centre, serving the whole country of Finland. The service counsels health care professionals and pregnant and lactating women about risks related to drug exposure. Pregnancies are followed up prospectively to outcome, and a follow-up questionnaire is sent to the mother/ health care provider after delivery. Data collected at the time of call include maternal characteristics (age, drug exposure, use of tobacco and alcohol and illicit drugs, BMI, chronic diseases, obstetric history and use of folic acid). The follow-up data include pregnancy data, pregnancy outcome data, and infant data (gestational age, birth weight, Apgar score, peri- and neonatal problems, malformations etc). In all pregnancies with first trimester exposure, and those with exposure to new drugs even in later stages of pregnancy, permission for follow-up is requested.
3. Category
University based
Hospital based
4. Available resources
In houseVia Contacts/Network
5. Therapeutic/disease areas of research in drug safety/risk-benefit performed in the past 5 years
Congenital Malformations
Pregnancy
6. Design of drug safety/risk-benefit studies published in the past 5 years
Cohort Study
Drug Utilisation
7. Experience in collecting data directly from individual patients/respondents
Number of Studies
Greater than 5
Number of patients/respondents involved in the study(ies)
Less than 150
8. Access to data collection resources
Capacity to conduct face-to-face interviews
No
Electronic data capture systems
Yes
System used:
LOTUS-based database
Interactive voice response systems
Yes
Call centre
Yes
9. Experience in secondary research and meta-analysis
No
10. Work with existing data resources in the past 3 years
Name of data resourceNo. of studies
National Birth Register, Malformation Register, Drug Prescription Register3
11. Registries established by centre
Drug RegistryDrugs used during pregnancy
12. Experience in collaboration in a study team
Collaborating Investigator
13. Current involvement in research networks
Networks registered with ENCePP
ENTIS
Other networks:
Network nameNationalInternationalLink to webpage
14. Interest in research opportunities which are funded
By government
By research councils
15. Interest in contract research only if free to publish results
Yes
16. Selected publications of the last 5 calendar years
ReferenceLink to web-publication
Malm H, Artama M, Gissler M, Ritvanen A. Selective Serotonin Reuptake Inhibitors and Risk for Major Congenital Anomalies. Obstet Gynecol 2011; 118:111-20.
